Volume 17, No 11, Nov 2007

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 17 Issue 11, November 2007: 933-941

ORIGINAL ARTICLES

Andrographolide inhibits NF-κB activation and attenuates neointimal hyperplasia in arterial restenosis

Yu-Jiu Wang^1,*, Jin-Tao Wang^2,*, Quan-Xin Fan¹ and Jian-Guo Geng²

¹Department of Cardiac Surgery, Shandong Provincial Hospital, Shandong University, Jinan 250021, China

²Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, The Graduate School of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China Correspondence: Jian-Guo, Geng(genglab@gmail.com)

The NF-κB transcription factors modulate the expression of tissue factor (TF), E-selectin (CD62E) and vascular cell adhesion molecule-1 (VCAM-1), which are essential for thrombosis and inflammation. We have previously shown that andrographolide (Andro) covalently modifies the reduced cysteine⁶² of p50 – a major subunit of NF-κB transcription factors, thus blocking the binding of NF-κB transcription factors to the promoters of their target genes, preventing NF-κB activation and inhibiting inflammation in vitro and in vivo. Here we report that Andro, but not its inactive structural analog 4H-Andro, significantly suppressed the proliferation of arterial neointima (κ60% reduction) in a murine model of arterial restenosis. Consistently, p50^-/- mice manifested attenuated neointimal hyperplasia upon arterial ligation. Notably, the same dosage of Andro did not further reduce neointimal formation in p50^-/- mice, which implicates the specificity of Andro on p50 for treating experimental arterial restenosis. The upregulation of NF-κB target genes, including TF, E-selectin and VCAM-1, and the increased deposition of leukocytes (mainly CD68⁺ macrophages) were clearly detected within the injured arterial walls, all of which were significantly abolished by treatment with Andro or genetic deletion of p50. The expression of TF, E-selectin and VCAM-1 was also markedly upregulated in the patient sample of thrombotic vasculitis, indicating the clinical relevance of NF-κB activation in the pathogeneses of occlusive arterial diseases. Our data thus indicate that, by the downregulation of the NF-κB target genes that are critical in thrombosis and inflammation, specific inhibitors of p50, such as Andro, may be therapeutically valuable for preventing and treating thrombotic arterial diseases, including neointimal hyperplasia in arterial restenosis.

Cell Research (2007) 17:933-941. doi: 10.1038/cr.2007.89; published online 16 October 2007

FULL TEXT | PDF

Browse 1791